Protagenic Therapeutics Stock Buy Hold or Sell Recommendation
| PTIXW Stock | USD 0.01 0 34.03% |
Assuming the 90 days horizon and your highly speculative risk level, our recommendation regarding Protagenic Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Protagenic Therapeutics given historical horizon and risk tolerance towards Protagenic Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Protagenic Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Protagenic Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide. Note, we conduct extensive research on individual companies such as Protagenic and provide practical buy, sell, or hold advice based on investors' constraints. Protagenic Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Protagenic |
Execute Protagenic Therapeutics Buy or Sell Advice
The Protagenic recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Protagenic Therapeutics. Macroaxis does not own or have any residual interests in Protagenic Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Protagenic Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Solid | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Protagenic Therapeutics Trading Alerts and Improvement Suggestions
| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics has accumulated about 671.09 K in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Protagenic Therapeutics Returns Distribution Density
The distribution of Protagenic Therapeutics' historical returns is an attempt to chart the uncertainty of Protagenic Therapeutics' future price movements. The chart of the probability distribution of Protagenic Therapeutics daily returns describes the distribution of returns around its average expected value. We use Protagenic Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Protagenic Therapeutics returns is essential to provide solid investment advice for Protagenic Therapeutics.
| Mean Return | 1.76 | Value At Risk | -41.67 | Potential Upside | 63.74 | Standard Deviation | 30.42 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Protagenic Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Protagenic Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 436.1K | (127.5K) | (129.9K) | (326.0K) | 1.1M | 1.1M | |
| Free Cash Flow | (488.0K) | (1.3M) | (2.8M) | (2.0M) | (3.9M) | (3.7M) | |
| Depreciation | 339.0 | 286.0 | 427.1K | 30.0 | 28.2K | 26.8K | |
| Other Non Cash Items | 110.9K | 154.9K | 346.0K | 156.8K | 716.1K | 680.3K | |
| Net Income | (1.8M) | (2.5M) | (4.5M) | (3.6M) | (5.0M) | (5.3M) | |
| End Period Cash Flow | 798.6K | 671.1K | 541.2K | 215.2K | 1.3M | 1.2M | |
| Investments | 250K | 0.0 | (9.9M) | 1.6M | 2.7M | 2.8M |
Protagenic Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Protagenic Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Protagenic Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Protagenic stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.30 | |
β | Beta against Dow Jones | -4.29 | |
σ | Overall volatility | 254.63 | |
Ir | Information ratio | 0.05 |
Protagenic Therapeutics Volatility Alert
Protagenic Therapeutics is showing large volatility of returns over the selected time horizon. Protagenic Therapeutics is a penny stock. Even though Protagenic Therapeutics may be a good instrument to invest, many penny stocks are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside scenarios of investing in Protagenic Therapeutics or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Protagenic instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Protagenic Therapeutics Fundamentals Vs Peers
Comparing Protagenic Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Protagenic Therapeutics' direct or indirect competition across all of the common fundamentals between Protagenic Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Protagenic Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Protagenic Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Protagenic Therapeutics to competition |
| Fundamentals | Protagenic Therapeutics | Peer Average |
| Return On Equity | -2.06 | -0.31 |
| Return On Asset | -0.9 | -0.14 |
| EBITDA | (4.5 M) | 3.9 B |
| Net Income | (5 M) | 570.98 M |
| Cash And Equivalents | 671.09 K | 2.7 B |
| Cash Per Share | 0.06 X | 5.01 X |
| Total Debt | 655.25 K | 5.32 B |
| Current Ratio | 1.34 X | 2.16 X |
| Book Value Per Share | 0.83 X | 1.93 K |
| Cash Flow From Operations | (3.7 M) | 971.22 M |
| Number Of Employees | 1 | 18.84 K |
| Beta | 0.25 | -0.15 |
| Total Asset | 4.32 M | 29.47 B |
| Retained Earnings | (30.78 M) | 9.33 B |
| Working Capital | 3.54 M | 1.48 B |
| Net Asset | 4.32 M |
Note: Acquisition by Musci Raymond of 1758 shares of Protagenic Therapeutics at 2.09 subject to Rule 16b-3 [view details]
Protagenic Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Protagenic . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Protagenic Therapeutics Buy or Sell Advice
When is the right time to buy or sell Protagenic Therapeutics? Buying financial instruments such as Protagenic Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Protagenic Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Sovereign ETFs Thematic Idea Now
Broad Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.